Nishiwaki, S
Imai, K
Mizuta, S
Kanamori, H
Ohashi, K
Fukuda, T
Onishi, Y
Takahashi, S
Uchida, N
Eto, T
Nakamae, H
Yujiri, T
Mori, S
Nagamura-Inoue, T
Suzuki, R
Atsuta, Y
Tanaka, J
,
Article History
Received: 8 June 2015
Accepted: 3 August 2015
First Online: 21 September 2015
Competing interests
: YO has received honoraria from Novartis and Bristol-Myers Squibb. ST has received honoraria and research funding from Novartis. NU has received honoraria from Otsuka Pharmaceutical Co., Kyowa Hakko Kirin Co., Chugai Pharmaceutical Co., Sumitomo Dainippon Pharma, Bristol-Myers Squibb, Daiichi Sankyo Company and Yakult Honsha, and travel, accommodations, expenses from Yakult Honsha and Kyowa Hakko Kirin Co. HN has received honoraria, speaker’s bureau, research funding, and travel, accommodations, expenses from Novartis and Bristol-Myers Squibb. TN-I has research funding from Tsubakimoto Co. and Wanbishi Archives Co. and patent pending with Tsubakimoto Co. YA has received honoraria from Otsuka Pharmaceutical Co., MDS Co. Ltd, Meiji Seika Pharma and Chugai Pharmaceutical Co., and travel, accommodations, expenses from Kyowa Hakko Kirin Co. The remaining authors declare no competing financial interests.